Source comparison
Quick Comparison
Type: CJC-1295 is a GHRH analog; Ipamorelin is a growth hormone secretagogue (GHRP). Mechanism: CJC-1295 activates GHRH receptors on pituitary somatotrophs; Ipamorelin activates ghrelin receptors (GHS-R1a) on pituitary somatotrophs. Receptor target: CJC-1295 t
This comparison does not assign a generated winner or score.
- Type: CJC-1295 is a GHRH analog; Ipamorelin is a growth hormone secretagogue (GHRP).
- Mechanism: CJC-1295 activates GHRH receptors on pituitary somatotrophs; Ipamorelin activates ghrelin receptors (GHS-R1a) on pituitary somatotrophs.
- Receptor target: CJC-1295 targets GHRH-R; Ipamorelin targets GHS-R1a.
- Half-life: CJC-1295 approximately 30 minutes without DAC, or 6 to 8 days with DAC; Ipamorelin approximately 2 hours.
- GH release pattern: CJC-1295 produces sustained elevation with preserved pulsatility; Ipamorelin produces a sharp, discrete GH pulse.
- Cortisol effect: Minimal for both — Ipamorelin shows no meaningful cortisol elevation even at doses 200 times the effective GH dose.
- Prolactin effect: Minimal for both.
- Appetite effect: None significant for either.
- Typical dose: CJC-1295 without DAC is 100 mcg one to two times daily; with DAC it is 1 to 2 mg weekly. Ipamorelin is 200 to 300 mcg one to three times daily.